Pharmaceutical products company Lannett Company Inc (NYSE:LCI) on Wednesday announced an agreement to be the exclusive US distributor of Posaconazole Delayed-Release Tablets 100mg from Sinotherapeutics Inc, a China-based specialty pharmaceutical company.
Lannett expects to commence shipping the US Food and Drug Administration (FDA) approved Posaconazole Delayed-Release Tablets 100mg shortly.
Sinotherapeutics' Posaconazole Delayed-Release Tablets 100mg is an AB-rated generic equivalent of Merck's Noxafil Delayed-Release Tablets for preventing certain fungal infections. The brand product's annual US sales were approximately USD325m for the 12 months ended June 2019, according to IQVIA.
Lannett will make milestone payments to Sinotherapeutics Inc based on market dynamics and performance.
Additionally, Lannett will provide sales, marketing and distribution and will receive a share of the profits. Other terms were not disclosed.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical